Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Levodopa-4'-monophosphate
Drug ID BADD_D01274
Description Foslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants With Advanced Parkinson's Disease).
Indications and Usage Not Available
Marketing Status Discontinued
ATC Code N04BA01
DrugBank ID DB16683
KEGG ID D00059
MeSH ID D007980
PubChem ID 127766
TTD Drug ID DP7GK8
NDC Product Code Not Available
Synonyms Levodopa | L-Dopa | L Dopa | 3-Hydroxy-L-tyrosine | 3 Hydroxy L tyrosine | L-3,4-Dihydroxyphenylalanine | L 3,4 Dihydroxyphenylalanine | Levopa | Larodopa | Dopaflex | Dopar
Chemical Information
Molecular Formula C9H12NO7P
CAS Registry Number 97321-87-4
SMILES C1=CC(=C(C=C1CC(C(=O)O)N)O)OP(=O)(O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionProtein c-FosP01100T28025Not Available
Dyskinesias and movement disorders NECE3 ubiquitin-protein ligase parkinO60260Not AvailableNot Available
Parkinson's diseaseOpioid growth factor receptorQ9NZT2T13741Not Available
Toxicity to various agentsCatechol O-methyltransferaseP21964T76904Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Arthralgia15.01.02.001--
Asthenia08.01.01.001--Not Available
Back pain15.03.04.005--
Blood uric acid increased13.02.04.001--Not Available
Constipation07.02.02.001--
Diarrhoea07.02.01.001--
Dizziness17.02.05.003; 02.01.02.004; 24.06.02.007--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Fatigue08.01.01.002--
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Gout14.09.01.001; 15.01.06.001--Not Available
Headache17.14.01.001--
Hypercalcaemia14.04.01.003; 05.04.01.002--
Hypercalciuria20.02.01.007; 14.04.01.006; 05.04.01.003--Not Available
Hyperuricaemia14.09.01.003--
Infection11.01.08.002--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Injection site erythema12.07.03.001; 08.02.03.001; 23.03.06.015--Not Available
Injection site irritation12.07.03.027; 08.02.03.027--Not Available
Muscle spasms15.05.03.004--
Nausea07.01.07.001--
Nephrolithiasis20.04.01.002--
Nervous system disorder17.02.10.001--Not Available
Pain in extremity15.03.04.010--
Palpitations02.01.02.003--
Parosmia22.04.03.007; 17.04.04.002--Not Available
Urethral disorder20.07.01.002--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages